Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

PURPOSE: To evaluate the use of blood cell–free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC). EXPERIMENTAL DESIGN: We used targeted sequencing (TS) to analyze 78 longitudinal cfDNA samples collected from 30 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lheureux, Stephanie, Prokopec, Stephenie D., Oldfield, Leslie E., Gonzalez-Ochoa, Eduardo, Bruce, Jeffrey P., Wong, Derek, Danesh, Arnavaz, Torti, Dax, Torchia, Jonathan, Fortuna, Alexander, Singh, Sharanjit, Irving, Matthew, Marsh, Kayla, Lam, Bernard, Speers, Vanessa, Yosifova, Aleksandra, Oaknin, Ana, Madariaga, Ainhoa, Dhani, Neesha C., Bowering, Valerie, Oza, Amit M., Pugh, Trevor J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502468/
https://www.ncbi.nlm.nih.gov/pubmed/37327320
http://dx.doi.org/10.1158/1078-0432.CCR-23-0797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502468/
https://www.ncbi.nlm.nih.gov/pubmed/37327320
http://dx.doi.org/10.1158/1078-0432.CCR-23-0797

Ejemplares similares